Astex Pharmaceuticals, Inc.

307 articles about Astex Pharmaceuticals, Inc.

• SuperGen, Inc. Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme

  8/7/2008

• SuperGen, Inc. Reports 2008 Second Quarter Financial Results

  8/6/2008

• SuperGen, Inc. (JOBS) Drug Dacogen Fails Trial; Likely Delay to European Nod

  7/2/2008

• SuperGen, Inc. to Present at the Piper Jaffray Europe Conference on June 25, 2008

  6/18/2008

• SuperGen, Inc.'s JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

  6/16/2008

• SuperGen, Inc.'s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

  6/13/2008

• SuperGen, Inc. to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008

  5/22/2008

• SuperGen, Inc. to Present at the Citi Investment Research Global Healthcare Conference on May 22, 2008

  5/16/2008

• SuperGen, Inc. Reports 2008 First Quarter Financial Results Dacogen Royalty Revenue Increases 114% from Same Prior Year Period

  4/29/2008

• SuperGen, Inc. to Webcast 3rd Annual Analyst Day on April 29, 2008

  4/22/2008

• SuperGen, Inc. to Announce 2008 First Quarter Financial Results April 28, 2008

  4/21/2008

• SuperGen, Inc. Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

  4/16/2008

• SuperGen, Inc.'s DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

  4/15/2008

• Data Show SuperGen, Inc.'s MP-470 is Safe in Humans

  4/15/2008

• SuperGen, Inc.'s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

  4/14/2008

• SuperGen, Inc. to Highlight Oncology Pipeline Data in Multiple Presentations at the American Association for Cancer Research Annual Meeting

  4/7/2008

• SuperGen, Inc. Reports 2007 Fourth Quarter and Annual Financial Results Company Achieves 2007 Net Income of $13.1 Million

  3/4/2008

• SuperGen, Inc. Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

  12/17/2007

• SuperGen, Inc.'s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting

  12/10/2007

• SuperGen, Inc.'s CLIMB(TM) Technology Identifies Lead Pim Kinase Inhibitors

  12/10/2007